Preventing Tumour Onset in Li-Fraumeni Syndrome by Inhibiting the Mechanistic Target of Rapamycin (mTOR)-Regulated Senescence-Associated Secretory Phenotype

通过抑制雷帕霉素 (mTOR) 调节的衰老相关分泌表型的机制靶点来预防 Li-Fraumeni 综合征的肿瘤发生

• 批准号: 386340
• 负责人: Giovino Camilla M
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-12-01 至 2018-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=386340&lang=en
• 关键词: Cancer Predisposition; Li-Fraumeni Syndrome; Malignant Transformation; Mtorc1 Signalling; Pharmacological Prevention Of Malignancy; Rapamycin; Senescence; Senescence-Associated Secretory Phenotype; Tp53

Individuals with Li-Fraumeni Syndrome (LFS) are prone to developing early-onset malignancies because the TP53 tumour suppressor gene is mutated in all of their cells. p53 promotes DNA repair, cell cycle arrest, and death of pre-malignant cells, making m

患有Li-Fraumeni综合征（LFS）的个体容易发生早发性恶性肿瘤，因为TP 53肿瘤抑制基因在所有细胞中发生突变。p53促进DNA修复、细胞周期阻滞和癌前细胞死亡，使肿瘤细胞增殖。